13F Holdings
中文EN

LQDA Liquidia Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1819576 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY2,233.6%
TTM net income YoY192.7%
TTM EPS YoY178.2%
Revenue 3-yr CAGR193.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin37.4%
Net margin30.7%
FCF margin33.4%
EBITDA margin37.7%

Returns

ROE131.8%
ROA35.6%
ROIC (approx.)—
Asset turnover1.16x

Leverage & solvency

Liabilities / assets62.6%
Debt / equity0.00x
Current ratio2.31x
Interest coverage6.33x

Cash quality & payout

Operating cash flow / net income1.21x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue3.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$158.32M$14.00M$17.49M$15.94M$12.85M
Cost of revenue—$5.88M$2.89M$2.86M$3.02M
Gross profit—$8.12M$14.60M$13.08M$9.83M
R&D expense$39.28M$47.84M$43.24M$19.43M$20.52M
SG&A expense$157.18M$81.57M$44.74M$32.41M$23.11M
Operating income-$51.38M-$121.29M-$73.38M-$38.77M-$33.80M
Interest expense$24.17M$14.65M$6.27M$2.34M$762,000
Income tax$0$0$0$0$0
Net income-$68.92M-$128.29M-$78.50M-$41.02M-$34.58M
EBITDA-$49.85M-$119.10M-$71.21M-$35.12M-$28.18M
EPS (basic)-0.80-1.63-1.21-0.67-0.70
EPS (diluted)-0.80-1.63-1.21-0.67-0.70
Weighted avg. shares (diluted)86.06M78.71M64.99M60.96M49.68M
Balance sheet
Cash & equivalents$190.68M$176.48M$83.68M$93.28M$57.49M
Receivables$54.09M$2.72M$4.06M$5.02M$2.99M
Inventory$23.80M$241,000$0——
Current assets$273.40M$185.10M$89.90M$99.81M$61.28M
PP&E, net$11.84M$8.30M$4.48M$4.15M$5.02M
Goodwill$3.90M$3.90M$3.90M$3.90M$3.90M
Intangibles$2.95M$3.16M$3.43M$3.73M$4.39M
Total assets$327.93M$230.31M$118.33M$129.20M$93.73M
Current liabilities$135.77M$41.78M$18.55M$8.80M$7.33M
Long-term debt———$19.88M$10.41M
Total debt———$19.88M$10.41M
Total liabilities$283.19M$150.94M$71.04M$38.78M$28.46M
Shareholders' equity$44.75M$79.38M$47.29M$90.42M$65.27M
Net debt———-$73.40M-$47.08M
Shares outstanding87.20M84.68M68.63M64.52M52.29M
Cash flow statement
Operating cash flow-$35.69M-$93.42M-$41.56M-$28.59M-$34.03M
Capital expenditure$4.34M$4.95M$1.29M$592,000$107,000
Free cash flow-$40.02M-$98.37M-$42.85M-$29.18M-$34.14M
Investing cash flow-$6.34M-$8.44M-$11.29M-$587,000-$107,000
Financing cash flow$59.73M$194.66M$43.25M$64.96M$26.32M
Depreciation & amortization$1.53M$2.20M$2.18M$3.65M$5.61M
Stock-based compensation$29.47M$18.81M$10.09M$9.30M$6.75M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.